93029-92-6

Upstream product

• 102-71-6 triethanolamine 
• 58202-84-9 N-(3-cyanophenyl)acetamide 
• 2237-30-1 m-cyanoaniline 

Downstream Products

• 91392-12-0 N-[3-(4-methyl-thiazol-2-yl)-phenyl]-acetamide 
• 873411-40-6 N-acetyl-sulfanilic acid-[3-(4-methyl-thiazol-2-yl)-anilide] 
• 134811-71-5 1-Ethyl-4-oxo-7-(4-phenyl-thiazol-2-yl)-1,4-dihydro-quinoline-3-carboxylic acid ethyl ester 
• 134811-81-7 1-Ethyl-4-oxo-7-(4-phenyl-thiazol-2-yl)-1,4-dihydro-quinoline-3-carboxylic acid 
• 134811-98-6 ethyl 4-hydroxy-7-(4-phenyl-2-thiazolyl)quinoline-3-carboxylate 
• 134811-95-3 2-(3-aminophenyl)-4-phenylthiazole 
• 134811-94-2 2-(3-aminophenyl)-4,5-dimethylthiazole 
• 134811-93-1 2-(3-aminophenyl)-4-methylthiazole 

Relevant academic research and scientific papers

SUBSTITUTED THIAZOLE DERIVATIVES BEARING 3-PYRIDYL GROUPS, PROCESS FOR PREPARING THE SAME AND USE THEREOF

The present invention provides a pharmaceutical composition having a steroid C17,20-lyase inhibitory activity, which is useful as a prophylactic or therapeutic agent of prostatism, tumor such as breast cancer and the like, more particularly, a steroid C17,20-lyase inhibitor containing a compound represented by the formula: wherein A1 is an aromatic hydrocarbon group optionally having substituents or a heterocyclic group optionally having substituents, one of A2 and A3 is a hydrogen atom, a halogen atom, a C1-4 aliphatic hydrocarbon group optionally having substituents or an optionally esterified carboxyl group, the other of A2 and A3 is an aromatic hydrocarbon group optionally having substituents or a heterocyclic group optionally having substituents, and at least one of A1, A2 and A3 is a 3-pyridyl group optionally having substituents, or a salt thereof or a prodrug thereof.